[go: up one dir, main page]

SG11201606689VA - Cyclopropylamines as lsd1 inhibitors - Google Patents

Cyclopropylamines as lsd1 inhibitors

Info

Publication number
SG11201606689VA
SG11201606689VA SG11201606689VA SG11201606689VA SG11201606689VA SG 11201606689V A SG11201606689V A SG 11201606689VA SG 11201606689V A SG11201606689V A SG 11201606689VA SG 11201606689V A SG11201606689V A SG 11201606689VA SG 11201606689V A SG11201606689V A SG 11201606689VA
Authority
SG
Singapore
Prior art keywords
cyclopropylamines
lsd1 inhibitors
lsd1
inhibitors
Prior art date
Application number
SG11201606689VA
Other languages
English (en)
Inventor
Liangxing Wu
Chunhong He
Ding-Quan Qian
Bo Shen
xiaozhao Wang
Wenqing Yao
Fenglei Zhang
Joel R Courter
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606689V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG11201606689VA publication Critical patent/SG11201606689VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201606689VA 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors SG11201606689VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939488P 2014-02-13 2014-02-13
US201462061283P 2014-10-08 2014-10-08
PCT/US2015/015706 WO2015123465A1 (fr) 2014-02-13 2015-02-12 Cyclopropylamines en tant qu'inhibiteurs de lsd1

Publications (1)

Publication Number Publication Date
SG11201606689VA true SG11201606689VA (en) 2016-09-29

Family

ID=52589819

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201606689VA SG11201606689VA (en) 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors
SG10201806849WA SG10201806849WA (en) 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors
SG10201908028S SG10201908028SA (en) 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201806849WA SG10201806849WA (en) 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors
SG10201908028S SG10201908028SA (en) 2014-02-13 2015-02-12 Cyclopropylamines as lsd1 inhibitors

Country Status (32)

Country Link
US (4) US9670210B2 (fr)
EP (2) EP3626713B1 (fr)
JP (2) JP6602778B2 (fr)
KR (1) KR102421235B1 (fr)
CN (2) CN111454188A (fr)
AU (2) AU2015217073B2 (fr)
CA (1) CA2939082C (fr)
CL (1) CL2016002027A1 (fr)
CR (2) CR20200199A (fr)
CY (1) CY1122415T1 (fr)
DK (1) DK3105218T3 (fr)
EC (1) ECSP16073190A (fr)
ES (2) ES2901711T3 (fr)
HR (1) HRP20192167T1 (fr)
HU (1) HUE046273T2 (fr)
IL (2) IL247134B (fr)
LT (1) LT3105218T (fr)
ME (1) ME03654B (fr)
MX (2) MX377273B (fr)
MY (1) MY183499A (fr)
PE (1) PE20161573A1 (fr)
PH (2) PH12020552066A1 (fr)
PL (1) PL3105218T3 (fr)
PT (1) PT3105218T (fr)
RS (1) RS59559B1 (fr)
SG (3) SG11201606689VA (fr)
SI (1) SI3105218T1 (fr)
SM (1) SMT201900680T1 (fr)
TW (2) TWI685483B (fr)
UA (1) UA126541C2 (fr)
WO (1) WO2015123465A1 (fr)
ZA (1) ZA201606275B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014306149B2 (en) 2013-08-06 2019-09-19 Imago Biosciences Inc. KDM1A inhibitors for the treatment of disease
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3105219B9 (fr) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
WO2015123465A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
RS66458B1 (sr) 2015-02-12 2025-02-28 Imago Biosciences Inc Kdm1a inhibitor i njegova primena u terapiji
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
KR20180011331A (ko) 2015-06-12 2018-01-31 오리존 지노믹스 에스.에이. Lsd1 억제제와 관련된 바이오마커 및 그의 용도
WO2017013061A1 (fr) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
PH12018500317B1 (en) * 2015-08-12 2023-01-11 Incyte Holdings Corp Salts of an lsd1 inhibitor
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
EP3397616B1 (fr) * 2015-12-29 2020-06-10 Mirati Therapeutics, Inc. Inhibiteurs de lsd1
EP3397756B1 (fr) 2015-12-30 2023-03-08 Novartis AG Thérapies à base de cellules effectrices immunitaires dotées d'une efficacité accrue
CA3017411C (fr) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinaisons d'inhibiteurs de lsd1 pour leur utilisation dans le traitement des tumeurs solides
CN107200706A (zh) * 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
WO2017195216A1 (fr) * 2016-05-09 2017-11-16 Jubilant Biosys Limited Composés cyclopropyl-amides utilisés comme inhibiteurs doubles de lsd1/hdac
CN107459476B (zh) * 2016-06-03 2022-06-24 中国科学院上海药物研究所 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
US11390590B2 (en) 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
WO2018083138A1 (fr) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarqueurs pharmacodynamiques pour traitement du cancer personnalisé à l'aide d'agents de modification épigénétique
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
EP3575285A4 (fr) * 2017-01-24 2020-08-12 Medshine Discovery Inc. Inhibiteur de lsd1, son procédé de préparation et son application
CN106860453A (zh) * 2017-02-17 2017-06-20 杨燕 一种治疗溃疡性结肠炎的药物组合物
JP7352284B2 (ja) 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
ES3001085T3 (es) 2017-08-03 2025-03-04 Oryzon Genomics Sa Métodos de tratar alteraciones del comportamiento
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
CA3103392A1 (fr) 2018-05-11 2019-11-14 Imago Biosciences, Inc. Inhibiteurs de kdm1a pour le traitement d'une maladie
US11944614B2 (en) 2018-05-15 2024-04-02 Regents Of The University Of Michigan Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
KR20210141933A (ko) 2019-03-20 2021-11-23 오리존 지노믹스 에스.에이. 경계성 인격 장애의 치료 방법
MX2021011254A (es) 2019-03-20 2021-10-01 Oryzon Genomics Sa Metodos de tratamiento del trastorno por deficit de atencion e hiperactividad.
EP3994280A1 (fr) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarqueurs et procédés pour le traitement personnalisé d'un cancer du poumon à petites cellules au moyen d'inhibiteurs de kdm1a
CN114502561B (zh) * 2019-09-29 2023-12-26 南昌弘益药业有限公司 Lsd1抑制剂
WO2021214502A1 (fr) * 2020-04-21 2021-10-28 Idience Co., Ltd. Procédé de préparation d'un dérivé de phtalazinone et de ses intermédiaires
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
CN118019735A (zh) 2021-08-18 2024-05-10 坎莫森特里克斯公司 作为ccr6抑制剂的芳基磺酰基化合物
WO2023023532A2 (fr) 2021-08-18 2023-02-23 Chemocentryx, Inc. (hydroxy)pipéridines d'arylsulfonyle en tant qu'inhibiteurs de ccr6
GB202115017D0 (en) 2021-10-20 2021-12-01 Univ London Queen Mary Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
EP4419093A1 (fr) 2021-10-20 2024-08-28 Queen Mary University of London Traitements séquentiels et biomarqueurs pour inverser la résistance à des inhibiteurs de kinase
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
WO2023217758A1 (fr) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Méthodes de traitement d'une tumeur maligne des gaines des nerfs périphériques (tmgnp) à l'aide d'inhibiteurs de lsd1
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN118787751A (zh) * 2023-04-12 2024-10-18 中国科学院上海药物研究所 Lsd1抑制剂与药物联用治疗癌症的用途
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7013068A (fr) 1969-09-17 1971-03-19
US4537889A (en) 1982-12-27 1985-08-27 Eli Lilly And Company Inotropic agents
US4614810A (en) * 1984-09-24 1986-09-30 Pennwalt Corporation 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
US4625040A (en) 1984-09-24 1986-11-25 Pennwalt Corporation N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
JPH032778Y2 (fr) 1986-12-15 1991-01-24
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
EP0649425B1 (fr) 1992-06-17 1999-03-10 PHARMACIA & UPJOHN COMPANY Oximes a substitution pyridino, pyrrolidino et azepino, utilisees comme agents anti-atherosclerotiques et anti-hypercholesterolemiques
JP2923139B2 (ja) 1992-10-05 1999-07-26 三井化学株式会社 製 剤
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP1050535A4 (fr) 1997-11-11 2001-04-25 Ono Pharmaceutical Co Composes de pyrazine condenses
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP2000319278A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP4041624B2 (ja) 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
KR100621281B1 (ko) 1999-09-28 2006-09-13 파나세아 바이오테크 리미티드 니메설라이드를 포함하는 방출제어형 조성물
SE9903611D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds III
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP4409680B2 (ja) 1999-10-18 2010-02-03 株式会社ヤクルト本社 三環性縮合イミダゾール誘導体
EP1277754B8 (fr) 2000-04-27 2005-09-28 Astellas Pharma Inc. Derives d'imidazopyridine
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
WO2002006286A2 (fr) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines destinees au traitement d'affections neurologiques
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2001295992A1 (en) 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
ATE310740T1 (de) 2000-11-10 2005-12-15 Merck Sharp & Dohme Imidazotriazin-derivate als liganden für gaba- rezeptoren
US20040058938A1 (en) 2000-12-13 2004-03-25 Oliver Cullmann Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
EP1217000A1 (fr) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibiteurs du factor Xa et factor VIIa
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
EP1377549A1 (fr) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Heterocycles fonctionnalises en tant que modulateurs de la fonction du recepteur de chimiokines et procedes de mise en oeuvre
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2003062392A2 (fr) 2002-01-18 2003-07-31 Ceretek Llc Procedes pour traiter des pathologies associees a un recepteur d'edg
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004017950A2 (fr) 2002-08-22 2004-03-04 Piramed Limited Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2005014777A2 (fr) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Procedes et compositions pour augmenter l'efficacite de substances actives d'un point de vue biologique
EP1572693A1 (fr) 2002-12-20 2005-09-14 Pharmacia Corporation Composes inhibant la proteine kinase-2 activee par la proteine kinase activee par des agents mitogenes
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP2385040A1 (fr) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Dérivés hétérocycliques renfermant de l'azote et médicaments contenant ces dérivés comme principe actif
WO2004089416A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Polytherapie utilisant un inhibiteur de type 1 de la 11beta-hydroxysteroide deshydrogenase et un agent hypotenseur dans le traitement du syndrome metabolique et des troubles et maladies associes
ES2338656T3 (es) 2003-04-11 2010-05-11 High Point Pharmaceuticals, Llc Uso farmaceutico de 1,2,4-triazoles fusionados.
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP2292620A3 (fr) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
CA2534312A1 (fr) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Derives de sulfonamide pour le traitement du diabete
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
JP4842829B2 (ja) 2003-10-31 2011-12-21 武田薬品工業株式会社 含窒素縮合複素環化合物
WO2005063241A1 (fr) 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. Agent pour prevenir et/ou de traiter des maladies faisant intervenir un recepteur de benzodiazepine mitochondrial
EP1717238A4 (fr) 2004-02-16 2008-03-05 Daiichi Seiyaku Co Composes heterocycliques fongicides
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
BRPI0510319A (pt) * 2004-04-26 2007-10-16 Pfizer inibidores da enzima integrase de hiv
ES2370729T3 (es) 2004-05-11 2011-12-22 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan.
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
BRPI0514391A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos de triazolopiridina para o tratamento de inflamação
JP2008511669A (ja) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
JP2008520719A (ja) 2004-11-22 2008-06-19 スレショルド ファーマシューティカルズ インコーポレイティッド チューブリン結合抗癌剤およびそれらのプロドラッグ
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
WO2007149479A1 (fr) 2006-06-22 2007-12-27 Mallinckrodt Inc. Dérivés de pyrazine et leurs utilisations dans la surveillance rénale
WO2006073938A2 (fr) 2004-12-30 2006-07-13 East Carolina University Procede de synthese de composes de indolizine 3-substituee et de benzoindolizine
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
EA012615B1 (ru) 2005-02-22 2009-10-30 Пфайзер Инк. Производные оксииндола в качестве агонистов 5-htрецептора
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
ATE480239T1 (de) 2005-06-09 2010-09-15 Oncalis Ag Angiogeneseinhibitoren
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TWI255587B (en) 2005-07-04 2006-05-21 Quanta Comp Inc Multi-frequency planar antenna
EP1928237A4 (fr) 2005-09-02 2011-03-09 Abbott Lab Nouveaux heterocycles a base imidazo
ES2349476T3 (es) 2005-09-09 2011-01-03 Schering Corporation Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
WO2007058942A2 (fr) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines inhibant la proteine kinase
CA2631233C (fr) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Formes galeniques de ganaxolone et procedes de preparation et d'utilisation de celles-ci
ES2376357T3 (es) 2005-12-27 2012-03-13 F. Hoffmann-La Roche Ag Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina.
WO2007074491A1 (fr) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena Derives d’amide heterotricycliques en tant que ligands du recepteur de neurokinine-1 (nk1)
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP2004643A1 (fr) 2006-03-31 2008-12-24 Novartis AG Composés organiques
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CA2654202A1 (fr) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines utilisees en tant qu'inhibiteur de proteine kinase
AU2007261397A1 (en) 2006-06-22 2007-12-27 Mallinckrodt Llc Pyrazine derivatives with extended conjugation and uses thereof
WO2008005262A1 (fr) 2006-06-29 2008-01-10 Schering Corporation Antagonistes de récepteur de la thrombine bicycliques et tricycliques substitués
WO2008005423A1 (fr) 2006-07-03 2008-01-10 Cambrex Charles City, Inc. Méthode améliorée de fabrication de sufentanil
WO2008005908A2 (fr) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Dérivés de pyridoïmidazole
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US20080021026A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (fr) 2006-09-25 2008-04-03 Basf Se Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes
AU2007307031B2 (en) 2006-10-11 2011-11-24 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
EP2079450A2 (fr) 2006-11-08 2009-07-22 Novavax, INC. Procédé pour préparer des formes de dosage solides de compositions pharmaceutiques à plusieurs phases
WO2008056176A1 (fr) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines utiles comme inhibiteurs de la phosphodiestérase
CN101641093B (zh) 2006-11-22 2013-05-29 因塞特公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
EP2086540B8 (fr) 2006-12-01 2011-03-02 Galapagos N.V. Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires
CA2673511A1 (fr) 2006-12-22 2008-07-03 Combinatorx, Incorporated Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentes
DK2118101T3 (da) 2007-03-09 2013-01-02 Probiodrug Ag IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
EP1972628A1 (fr) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines et leurs dérivés aza analogues en tant que composés actifs du SNC
ATE540037T1 (de) 2007-04-16 2012-01-15 Leo Pharma As Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
WO2008141249A1 (fr) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines et composés associés à activité au niveau des récepteurs cannabinoïdes cb2
WO2008143240A1 (fr) 2007-05-21 2008-11-27 Toray Industries, Inc. Préparation orale renfermant un acide organique spécifique et procédé d'amélioration de la propriété d'élution et de la stabilité chimique de la préparation orale
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2167491A1 (fr) 2007-06-08 2010-03-31 Abbott Laboratories Indazoles à substitution 5-hétéroaryle servant d'inhibiteurs de kinases
MX2009013729A (es) 2007-06-14 2010-01-25 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
BRPI0813831A2 (pt) 2007-07-18 2015-01-06 Novartis Ag Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
CA2694218A1 (fr) 2007-07-31 2009-02-05 Schering Corporation Combinaison d'agent antimitotique et d'inhibiteur de l'aurora kinase comme traitement anti-cancer
WO2009017954A1 (fr) 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US20090047336A1 (en) 2007-08-17 2009-02-19 Hong Kong Baptist University novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
FR2920091A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier.
FR2920090A1 (fr) 2007-08-24 2009-02-27 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier.
KR20090022616A (ko) 2007-08-31 2009-03-04 한올제약주식회사 베실산클로피도그렐 함유 경구투여용 약제
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2522365T3 (es) 2007-10-11 2014-11-14 Astrazeneca Ab Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
CA2925175A1 (fr) 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)
PT2231662E (pt) 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
KR100988233B1 (ko) 2007-12-26 2010-10-18 한미홀딩스 주식회사 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 置換ヘテロ環縮合ガンマ−カルボリン類固体
WO2009114180A1 (fr) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
EP2444403A1 (fr) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Composé hétérocyclique doté d'une activité inhibitrice sur PI3K
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US8349210B2 (en) 2008-06-27 2013-01-08 Transitions Optical, Inc. Mesogenic stabilizers
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
WO2010033906A2 (fr) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Induction efficace de cellules souches pluripotentes au moyen de composés à petite molécule
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
EP2376490B1 (fr) 2008-12-04 2013-01-23 Proximagen Limited Composés imidazopyridines
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010084160A1 (fr) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
US8598163B2 (en) 2009-02-04 2013-12-03 Vitae Pharmaceuticals, Inc. Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
US20100209489A1 (en) 2009-02-04 2010-08-19 Supernus Pharmaceuticals, Inc. Formulations of desvenlafaxine
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
TR200900879A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
CA2752114C (fr) 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Pyrimidines condensees en tant qu'inhibiteurs d'akt
KR20100101056A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2010107404A1 (fr) 2009-03-16 2010-09-23 Mahmut Bilgic Combinaisons pharmaceutiques stables
TW201035078A (en) 2009-03-20 2010-10-01 Incyte Corp Substituted heterocyclic compounds
HRP20130846T1 (hr) 2009-03-31 2013-11-22 Kissei Pharmaceutical Co., Ltd. Derivati indolizina i njihova uporaba u medicinske svrhe
NZ596185A (en) 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
TWI461426B (zh) 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
JP2012529529A (ja) 2009-06-10 2012-11-22 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
PE20170003A1 (es) 2009-08-17 2017-03-15 Intellikine Llc Compuestos heterociclicos y usos de los mismos
EP2467359A4 (fr) 2009-08-18 2013-01-09 Univ Johns Hopkins Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
WO2011033265A1 (fr) 2009-09-18 2011-03-24 Almac Discovery Limited Composés pharmaceutiques
CA2812683C (fr) 2009-09-25 2017-10-10 Oryzon Genomics S.A. Inhibiteurs de demethylase-1 specifique de la lysine et leur utilisation
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
WO2011050245A1 (fr) 2009-10-23 2011-04-28 Yangbo Feng Hétéroaryles bicycliques formant inhibiteurs de la kinase
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
CA2787714C (fr) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibiteurs de la pi3 kinase
WO2011097607A1 (fr) 2010-02-08 2011-08-11 Southern Research Institute Traitement antiviral et dosage pour cribler des antiviraux
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN102869661B (zh) 2010-03-18 2015-08-05 韩国巴斯德研究所 抗感染化合物
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
WO2011121137A1 (fr) 2010-04-02 2011-10-06 Euroscreen S.A. Nouveaux composés antagonistes sélectifs du récepteur nk-3, composition pharmaceutique et méthodes pour une utilisation dans des troubles à médiation par des récepteurs nk-3
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
WO2011131576A1 (fr) 2010-04-20 2011-10-27 Università Degli Studi Di Roma "La Sapienza" Dérivés de tranylcypromine comme inhibiteurs de l'histone déméthylase lsd1 et/ou lsd2
JPWO2011136264A1 (ja) 2010-04-28 2013-07-22 第一三共株式会社 ［５，６］複素環化合物
WO2011141713A1 (fr) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) Nouveaux composés bicycliques en tant qu'inhibiteurs de pi3-k et de mtor
MX2012013130A (es) 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
CN102247321A (zh) 2010-05-20 2011-11-23 上海亚盛医药科技有限公司 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法
WO2011149438A1 (fr) 2010-05-28 2011-12-01 Mahmut Bilgic Combinaison d'agents antihypertenseurs
CN102295642B (zh) 2010-06-25 2016-04-06 中国人民解放军军事医学科学院毒物药物研究所 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
WO2012003392A1 (fr) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Composés hétérocycliques condensés en tant que modulateurs des canaux ioniques
ES2552841T3 (es) 2010-07-12 2015-12-02 Bayer Intellectual Property Gmbh Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
WO2012009475A1 (fr) 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
CN101987082B (zh) 2010-07-16 2013-04-03 钟术光 固体制剂及其制备方法
BR112013002164B1 (pt) * 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
WO2012016133A2 (fr) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
EP2598480B1 (fr) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
CN102397552B (zh) 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
WO2012034116A2 (fr) 2010-09-10 2012-03-15 The Johns Hopkins University Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles
ES2549926T3 (es) 2010-09-29 2015-11-03 Kissei Pharmaceutical Co., Ltd. Derivados (aza)indolizínicos como inhibidores de la xantina-oxidasa
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012047852A2 (fr) 2010-10-07 2012-04-12 The J. David Gladstone Institutes Compositions et procédés de modulation de la transcription de virus d'immunodéficience
WO2012054233A1 (fr) 2010-10-18 2012-04-26 E. I. Du Pont De Nemours And Company Sulfamides nématicides
KR20180069132A (ko) 2010-10-21 2018-06-22 메디베이션 테크놀로지즈 엘엘씨 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
WO2012052745A1 (fr) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral
WO2012071469A2 (fr) 2010-11-23 2012-05-31 Nevada Cancer Institute Inhibiteurs d'histone déméthylase et utilisations de ceux-ci pour le traitement de cancer
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
WO2012080727A2 (fr) 2010-12-14 2012-06-21 Electrophoretics Limited Inhibiteurs de caséine kinase 1 delta (ck1delta)
CN103429592A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
CA2821817A1 (fr) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6-imidazopyrazines substituees pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperproliferation
WO2012080230A1 (fr) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines 6-substituées pour l'utilisation en tant qu'inhibiteurs de mps-1 et de tkk dans le traitement de troubles d'hyperprolifération
JP5822944B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
WO2012088438A1 (fr) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utilisables en vue du traitement de maladies
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012100229A2 (fr) 2011-01-21 2012-07-26 The General Hospital Corporation Compositions et procédés contre les maladies cardiovasculaires
BRPI1100101B1 (pt) 2011-01-28 2020-10-20 Universidade De São Paulo Usp anel oito articulado
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
EP2712315B1 (fr) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour des troubles myéloprolifératifs
EP2678016B1 (fr) 2011-02-23 2016-08-10 Intellikine, LLC Composés hétérocycliques et leurs utilisations
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012135113A2 (fr) 2011-03-25 2012-10-04 Glaxosmithkline Llc Cyclopropylamines en tant qu'inhibiteurs de lsd1
WO2012147890A1 (fr) 2011-04-27 2012-11-01 持田製薬株式会社 Nouveau dérivé d'azole
EP2741741A2 (fr) 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase destinés au traitement de maladies ou états inflammatoires
US20140296255A1 (en) 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
EP2524918A1 (fr) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines en tant qu'inhibiteurs de kinase
WO2012168882A1 (fr) 2011-06-07 2012-12-13 SPAI Group Ltd. Compositions et procédés pour améliorer la stabilité et l'extension de la durée de conservation d'additifs alimentaires sensibles et produits alimentaires de ceux-ci
WO2012177606A1 (fr) 2011-06-20 2012-12-27 Incyte Corporation Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak
TW201311149A (zh) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
WO2013022047A1 (fr) 2011-08-09 2013-02-14 武田薬品工業株式会社 Composés de cyclopropanamine
BR112014003382B1 (pt) 2011-08-15 2022-03-15 University Of Utah Research Foundation Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
WO2013033515A1 (fr) 2011-09-02 2013-03-07 Promega Corporation Composés et procédés pour évaluer l'état redox de cellules métaboliquement actives et procédés de mesure de nad(p)/nad(p)h
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
CL2014000988A1 (es) 2011-10-20 2014-11-03 Oryzon Genomics Sa Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
EP2768805B1 (fr) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropyl comme inhibiteurs de lsd1
ITMI20111971A1 (it) 2011-10-28 2013-04-29 Mesogenics Srl Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico
EP2785183B1 (fr) 2011-11-14 2018-12-19 Merck Sharp & Dohme Corp. Inhibiteurs de pde10 de triazolopyridinone
CA2857964A1 (fr) 2011-12-05 2013-06-13 Brandeis University Traitement de l'amyloidose au moyen de composes qui regulent la stabilisation de retromeres
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN102579381B (zh) 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
PT3495367T (pt) * 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
EP2867226B1 (fr) 2012-06-28 2018-11-14 Novartis AG Modulateurs de la voie du complément et leurs utilisations
CN102772444A (zh) 2012-07-06 2012-11-14 周明千 中药超微破壁口服片剂饮片的加工方法
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
AU2013324396B2 (en) 2012-09-28 2018-10-04 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
CN104837832B (zh) 2012-10-05 2019-04-26 里格尔药品股份有限公司 Gdf-8抑制剂
US9751885B2 (en) 2012-10-12 2017-09-05 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
WO2014078479A2 (fr) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition de l'hétérodimérisation de hif-2α avec hif1β (arnt)
WO2014084298A1 (fr) 2012-11-28 2014-06-05 京都府公立大学法人 Inhibiteur sélectif de lsd1 à structure lysine
US9144555B2 (en) 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
EP2740474A1 (fr) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Dérivés de cyclopropylamine utiles comme inhibiteurs d'histone-déméthylases kdm1a
CN104994864B (zh) 2012-12-19 2018-05-29 沃克哈特有限公司 包含人胰岛素或其类似物或衍生物的稳定水性组合物
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
CN103933036B (zh) 2013-01-23 2017-10-13 中国人民解放军军事医学科学院毒物药物研究所 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2014164867A1 (fr) 2013-03-11 2014-10-09 Imago Biosciences Inhibiteurs de kdm1a pour le traitement d'une maladie
WO2014138791A1 (fr) 2013-03-13 2014-09-18 Australian Nuclear Science And Technology Organisation Organismes non humains transgéniques ayant des gènes tspo non fonctionnels
US20140343118A1 (en) 2013-03-14 2014-11-20 Duke University Methods of treatment using arylcyclopropylamine compounds
US20160045531A1 (en) 2013-03-14 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
WO2014194280A2 (fr) 2013-05-30 2014-12-04 The Board of Regents of the Nevada System of Higher Education on behalf of the University of Nouveaux inhibiteurs suicides de la lsd1 ciblant les cellules cancéreuses exprimant le sox2
MX366949B (es) 2013-06-19 2019-07-30 Univ Utah Res Found Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (fr) 2013-08-30 2015-03-05 University Of Utah Composés de la série des 1h-benzo[d]imidazoles substitués à titre d'inhibiteurs de déméthylase 1 spécifique de la lysine (lsd1)
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
HUE035877T2 (en) 2013-09-13 2018-05-28 Bayer Pharma AG Pharmaceutical preparations containing Refametinib
KR101568724B1 (ko) 2013-11-13 2015-11-12 서울대학교산학협력단 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도
WO2015089192A1 (fr) 2013-12-11 2015-06-18 Quanticel Pharmaceuticals, Inc. Inhibiteur de la déméthylase-1 spécifique de la lysine
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123465A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
EP3105219B9 (fr) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
WO2015145145A1 (fr) 2014-03-24 2015-10-01 Cipla Limited Composition pharmaceutique contenant du lapatinib
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
WO2015153720A1 (fr) 2014-04-02 2015-10-08 Bristol-Myers Squibb Company Inhibiteurs biaryle de kinase
WO2015155281A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et d'inhibiteurs de la pompe à protons
EP3129369A1 (fr) 2014-04-11 2017-02-15 Takeda Pharmaceutical Company Limited Composé de cyclopropanamine et son utilisation
EP2929884A1 (fr) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Combinaisons pharmaceutiques de dabigatran et antagonistes du récepteur de h2
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
WO2015181380A1 (fr) 2014-05-30 2015-12-03 Ieo - Istituto Europeo Di Oncologia S.R.L. Composés de cyclopropylamine à utiliser en tant qu'inhibiteurs de l'histone déméthylase
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN104173313B (zh) 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
JP6653116B2 (ja) 2014-08-27 2020-02-26 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
BR112017006829B1 (pt) 2014-10-08 2023-01-31 F. Hoffmann-La Roche Ag Derivados de espirodiamina como inibidores de aldosterona sintase
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
JP2018519245A (ja) 2015-04-03 2018-07-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
CA2980395A1 (fr) 2015-04-03 2016-10-06 Mutabilis Composes heterocycliques et leur utilisation dans la prevention ou le traitement d'infections bacteriennes
PH12018500317B1 (en) 2015-08-12 2023-01-11 Incyte Holdings Corp Salts of an lsd1 inhibitor
CN112656772B (zh) 2015-10-15 2022-05-20 浙江东日药业有限公司 利伐沙班药物组合物
EP3397616B1 (fr) 2015-12-29 2020-06-10 Mirati Therapeutics, Inc. Inhibiteurs de lsd1
JPWO2017130933A1 (ja) 2016-01-25 2018-11-29 国立大学法人 熊本大学 神経変性疾患治療剤
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
BR112019014759A2 (pt) 2017-01-18 2020-03-03 Vanderbilt University Compostos heterocíclicos fundidos como inibidores seletivos de bmp
RU2764655C2 (ru) 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation

Also Published As

Publication number Publication date
TWI741478B (zh) 2021-10-01
MX2016010395A (es) 2017-02-28
US20170342070A1 (en) 2017-11-30
NZ723817A (en) 2021-01-29
HRP20192167T1 (hr) 2020-02-21
CR20160396A (es) 2016-12-20
AU2015217073A1 (en) 2016-09-15
CL2016002027A1 (es) 2017-01-20
EP3626713A1 (fr) 2020-03-25
MX2020012046A (es) 2021-01-29
RS59559B1 (sr) 2019-12-31
PL3105218T3 (pl) 2020-03-31
US20190211014A1 (en) 2019-07-11
ME03654B (fr) 2020-07-20
CA2939082A1 (fr) 2015-08-20
TWI685483B (zh) 2020-02-21
KR20160132409A (ko) 2016-11-18
TW202033497A (zh) 2020-09-16
ZA201606275B (en) 2022-08-31
DK3105218T3 (da) 2019-11-04
EP3105218A1 (fr) 2016-12-21
JP2020019812A (ja) 2020-02-06
US9670210B2 (en) 2017-06-06
AU2015217073B2 (en) 2019-08-22
EP3626713B1 (fr) 2021-09-29
CN111454188A (zh) 2020-07-28
MX377273B (es) 2025-03-07
CN106164066B (zh) 2020-01-17
JP6883635B2 (ja) 2021-06-09
CY1122415T1 (el) 2021-01-27
CA2939082C (fr) 2022-06-07
US20210032244A1 (en) 2021-02-04
PH12016501601A1 (en) 2016-10-03
PH12020552066A1 (en) 2022-05-11
SMT201900680T1 (it) 2020-01-14
HUE046273T2 (hu) 2020-02-28
CR20200199A (es) 2020-06-19
WO2015123465A1 (fr) 2015-08-20
US11247992B2 (en) 2022-02-15
JP2017510554A (ja) 2017-04-13
IL277167A (en) 2020-10-29
ES2901711T3 (es) 2022-03-23
SG10201908028SA (en) 2019-10-30
BR112016018544A2 (pt) 2020-06-02
US20150225401A1 (en) 2015-08-13
KR102421235B1 (ko) 2022-07-15
LT3105218T (lt) 2019-12-10
IL277167B (en) 2021-08-31
TW201623231A (zh) 2016-07-01
US10174030B2 (en) 2019-01-08
SI3105218T1 (sl) 2019-11-29
US10717737B2 (en) 2020-07-21
EP3105218B1 (fr) 2019-09-25
ECSP16073190A (es) 2017-05-31
IL247134A0 (en) 2016-09-29
CN106164066A (zh) 2016-11-23
JP6602778B2 (ja) 2019-11-06
UA126541C2 (uk) 2022-11-02
AU2019210624B2 (en) 2021-06-10
ES2760261T3 (es) 2020-05-13
PT3105218T (pt) 2019-12-05
AU2019210624A1 (en) 2019-08-22
MY183499A (en) 2021-02-22
BR112016018544A8 (pt) 2023-01-24
SG10201806849WA (en) 2018-09-27
IL247134B (en) 2020-09-30
PE20161573A1 (es) 2017-01-19

Similar Documents

Publication Publication Date Title
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL287113A (en) smyd inhibitors
IL260217B (en) lsd1 driven
IL250642A0 (en) glycosidase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL246362A0 (en) Novel glutaminase inhibitors
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
EP3116503A4 (fr) Inhibiteurs de hptp-bêta
GB201421088D0 (en) New enzyme inhibitors
EP3183255C0 (fr) Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2
GB201421085D0 (en) New enzyme inhibitors
GB201403536D0 (en) Inhibitor compounds
GB201501004D0 (en) Inhibitors
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
GB201520949D0 (en) Inhibitors
GB201401005D0 (en) Inhibitor
EP3180003A4 (fr) Inhibiteurs de pkc-epsilon
GB201418154D0 (en) Inhibitors
HK1239455A1 (en) Smyd inhibitors
AU2014900536A0 (en) Inhibitors
AU2014900535A0 (en) Inhibitors